MECHANISTIC CONSIDERATIONS IN CANCER RISK ASSESSMENT

REFERENCES

• Ames, B. N. 1973. Carcinogens are mutagens: A simple test system combining liver homogenates for activation and bacteria for detection. Proc. Natl. Acad. Sci. USA 70:2281–2285.
   PubMed Web of Science ®Google Scholar
• Cohen, S. M., and Ellwein, L. B. 1990. Proliferative and genotoxic cellular effects in 2-acetylamina-fluorene bladder and liver carcinogenesis: Biological modeling of the ED01 study. Toxicol. Appl. Pharmacol. 104:79–93.
   PubMed Web of Science ®Google Scholar
• Enzmann, H., Zerban, H., Kopp-Schneider,A., Loser, A., and Bannasch, P. 1995. Effects of low doses of N-nitrosomorpholine on the development of early stages of hepatocarcinogenesis. Carcinogenesis 16:1513–1418.
   PubMedGoogle Scholar
• Gold, L. S., Manley, N., Slone, T., Garfinkel, G., Rohrback, L., and Ames, B. N. 1993. The fifth plot of the carcinogenic potency database: Results of animal bioassays published in the general liter-ature through 1988, by the National Toxicology Program through 1989. Environ. Health Perspect. 100:65–135.
   PubMed Web of Science ®Google Scholar
• Goodman, J. I. 1994. A rational approach to risk assessment requires the use of biological informa-tion: An analysis of the National Toxicology Program (NTP) final report of the advisory review by the NTP Board of Scientific Counselors. ReguL ToxicoL PharmacoL 19:51–59.
   PubMed Web of Science ®Google Scholar
• Hino, 0., and Kitagawa, T. 1981. Existence of a practical threshold dose for the hepatocarcinogen 3'-methyl-4-(dimethylamino)azabenzene in rat liver. Cann 72:637–638.
   Google Scholar
• International Agency for Research in Cancer. 1982. IARC Monogr. Eval. Carcinogen. Risk Chem. Man, Vol. 1-29, Suppl. 4, p. 13. Lyon, France: IARC.
   Google Scholar
• International Expert Panel on Carcinogen Risk Assessment. 1996. The use of mechanistic data in the risk assessment of ten chemicals. Pharmacol. Ther. 71 (Special Issue):1–5.
   Google Scholar
• Miller, E. C., and Miller, J. A. 1979. Milestones in chemical carcinogenesis. Sem. Oncol. 6:445–460.
   PubMed Web of Science ®Google Scholar
• Page, N. P., Singh, D. V., Farland, W., Goodman, J. I., Conolly, R. B., Anderson, M. E., Clewell, H. J., Frederick, C. B., Yamasaki, H., and Lucier, G. 1997. Implementation of EPA revised cancer assessment guidelines: Incorporation of mechanistic and pharmacokinetic data. Fundam. Appl. Toxicol. 37:16–36.
   PubMedGoogle Scholar
• Poirier, M. C., and Beland, F. A. 1994. DNA adduct measurements and tumor incidence during chronic carcinogen exposure in rodents. Environ. Health Perspect. 102:161–165.
   PubMedGoogle Scholar
• Presidential/Congressional Commission on Risk Assessment and Risk Management. 1997. Risk assess-ment and risk management in regulatory decision-making Vol. 2. Washington, DC: US Govern-ment Printing Office.
   Google Scholar
• Root, M., Lange, T., and Campbell, T. C. 1997. Dissimilarity in aflatoxin dose-response relationships between DNA adduct formation and development of preneoplastic foci in rat liver. Chem. Biol. Interact. 106:213–227.
   PubMedGoogle Scholar
• Umemura, T., Tokumo, K., Gebhardt, R., Poirier, M., and Williams, G. M. 1993. Dose response effects of 2-acetylaminofluorene on DNA damage, cytotoxicity, cell proliferation and neoplastic conversion in rat liver. Cancer Lett. 73:1–10.
   PubMed Web of Science ®Google Scholar
• Weisburger, J. H., and Williams, G. M. 1981. Carcinogen testing: Current problems and new approaches. Science214:401–407.
   PubMed Web of Science ®Google Scholar
• Weisburger, J. H., and Williams, G. M. 1983. The distinct health risk analyses required for genotoxic carcinogens and promoting agents. Environ. Health Perspect. 50:233–245.
   PubMedGoogle Scholar
• Whysner, J., and Williams, G. M. 1992. International cancer risk assessment: The impact of biologic mechanisms. Reg. Toxicol. PharmacoL 15:41–50.
   PubMedGoogle Scholar
• Whysner, J., Ross, P. M., and Williams, G. M. 1996. Phenobarbital mechanistic data and risk assess-ment: Enzyme induction, enhanced cell proliferation, and tumor promotion. Pharm. Ther. 71:153–192.
   PubMed Web of Science ®Google Scholar
• Williams, G. M. 1987. Definition of a human cancer hazard. In Nongenotoxic mechanisms in car-cinogenesis, pp. 367–380. Banbury Report 25. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory.
   Google Scholar
• Williams, G. M., and Weisburger, J. H. 1986. Chemical carcinogens. In Casarett and Doull's toxicol-ogy: The basic sciences of poison, 3rd Ed., eds. C. D. Klaassen, M. 0. Amdur, and J. Doull, pp. 99–173. New York: Macmillan.
   Google Scholar
• Williams, G. M., and Whysner, J. 1996. Epigenetic carcinogens: Evaluation and risk assessment. Exp. Toxicol. PathoL 48:189–195.
   PubMed Web of Science ®Google Scholar
• Williams, G. M., Gebhardt, R., Shirma, H., and Stenback, F. 1993. Non-linearity of neoplastic con-version induced in rat liver by low exposures to diethylnitrosamine. Carcinogenesis 14:2149–2156.
   PubMedGoogle Scholar
• Williams, G. M., latropoulos, M. J., and Weisburger, J. H. 1996a. Chemical carcinogen mechanisms of action and implications for testing methodology. Exp. ToxicoL PathoL 48:101–111.
   PubMed Web of Science ®Google Scholar
• Williams, G. M., latropoulos, M. J., Wang, C. X., Rivenson, A., Peterson, L. A., Schulz, C., and Gebhardt, R. 1996b. Diethylnitrosamine exposure-responses for DNA damage, centrilobular, cytotoxicity, cell proliferation and carcinogenesis in rat liver exhibit nonlinearities. Carcinogenesis 17:2253–2258.
   PubMed Web of Science ®Google Scholar